PMID- 23270579
OWN - NLM
STAT- MEDLINE
DCOM- 20140306
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 54
IP  - 9
DP  - 2013 Sep
TI  - Biologically defined risk groups can be used to define the impact of thalidomide 
      maintenance therapy in newly diagnosed multiple myeloma.
PG  - 1975-81
LID - 10.3109/10428194.2012.760736 [doi]
AB  - Maintenance therapy is an attractive strategy for patients with multiple myeloma. 
      However, the impact of maintenance thalidomide according to the underlying 
      biology of the disease is still a matter of debate, with some studies suggesting 
      that thalidomide is more beneficial in high risk disease, whilst others show the 
      opposite. Biological risk groups defined by interphase fluorescence in situ 
      hybridization (FISH) are powerful predictors of outcome. In this report we 
      investigated the effect of maintenance thalidomide in different biological risk 
      groups defined by different FISH categories. Our data show that maintenance 
      thalidomide improves outcome in patients with biologically low risk disease, 
      defined by the absence of adverse cytogenetic lesion or by the presence of 
      hyperdiploidy alone. Conversely, thalidomide maintenance is detrimental for the 
      overall survival of patients with biological high risk. We conclude that it is 
      important to identify biologically low risk patients who will benefit from a 
      maintenance strategy with thalidomide.
FAU - Brioli, Annamaria
AU  - Brioli A
AD  - Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of 
      Cancer Research, London, UK.
FAU - Kaiser, Martin F
AU  - Kaiser MF
FAU - Pawlyn, Charlotte
AU  - Pawlyn C
FAU - Wu, Ping
AU  - Wu P
FAU - Gregory, Walter M
AU  - Gregory WM
FAU - Owen, Roger
AU  - Owen R
FAU - Ross, Fiona M
AU  - Ross FM
FAU - Jackson, Graham H
AU  - Jackson GH
FAU - Cavo, Michele
AU  - Cavo M
FAU - Davies, Faith E
AU  - Davies FE
FAU - Morgan, Gareth J
AU  - Morgan GJ
LA  - eng
PT  - Journal Article
DEP - 20130123
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Immunosuppressive Agents)
RN  - 4Z8R6ORS6L (Thalidomide)
SB  - IM
MH  - Aged
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - In Situ Hybridization, Fluorescence
MH  - Maintenance Chemotherapy
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/diagnosis/*drug therapy/mortality
MH  - Neoplasm Staging
MH  - Thalidomide/*therapeutic use
MH  - Translocation, Genetic
MH  - Treatment Outcome
EDAT- 2012/12/29 06:00
MHDA- 2014/03/07 06:00
CRDT- 2012/12/29 06:00
PHST- 2012/12/29 06:00 [entrez]
PHST- 2012/12/29 06:00 [pubmed]
PHST- 2014/03/07 06:00 [medline]
AID - 10.3109/10428194.2012.760736 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2013 Sep;54(9):1975-81. doi: 10.3109/10428194.2012.760736. Epub 
      2013 Jan 23.